Australia Antimicrobial Resistance Market, by Drug Class (Combination therapies, Tetracyclines, Cephalosporins, Glycopeptides and Lipoglycopeptides, Oxazolidinones, Others), by Pathogen (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp, Others), by Indication (Complicated Urinary Tract Infections (cUTI), Blood stream infections, Acute bacterial skin and skin structure infections (ABSSSI), Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), Community acquired pneumonia (CAP), Others), by Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, Others): Opportunity Analysis and Industry Forecast, 2022-2032

The study on the Australia antimicrobial resistance market offers insights, information, and recommendation to market stakeholders and investors to help them prioritize and formulate strategic decisions. The study is analyzed on the basis of rigorous research methodology, which covers extensive desk research using qualitative analysis, quantitative/statistical methods, and primary interviews.

The study analyzes the market scope, revenue size, and growth of the Australia antimicrobial resistance market and monitors the prime trends at the national level. In addition, it covers qualitative analysis on the basis of several parameters, including impact on market size, economic impact, regulatory framework, opportunity window, and key player strategies. The report includes a section on the company profile that covers the company overview, company snapshot, key executives, product/service portfolio, operating business segments, business performance, R&D expenditure, and key strategic moves & developments. The Australia antimicrobial resistance market is categorized on the basis of indication, drug class, mechanism of action, pathogen.

COVID-19 Impact Analysis

The outbreak of COVID-19 has had a severe impact on the global economy and social development. The report includes micro and macro economic analyses along with qualitative analysis of the COVID-19 impact on the Australia antimicrobial resistance market. In addition, the report highlights the market size and share that reflects the COVID-19 impact on the Australia antimicrobial resistance market in 2020 and the subsequent years. Moreover, the report offers the key strategies adopted by market players during such unprecedented times. Furthermore, the roll-out of vaccines and the decline in risk of infection are also expected to have an impact on the Australia antimicrobial resistance market growth. Therefore, the report provides post-COVID-19 impact analysis.

Deliverables:

• Market size value forecast across the country

• Market trends and market dynamics

• Porter’s five forces model and PESTLE Analysis

• Company profile, competition landscape inclusive of heatmap analysis, competition dashboard, product/service offerings

• Major developmental strategies and M&A activities

• Market size and forecast for each segment

• Market share of leading players

Market Taxonomy

This report divides the Australia antimicrobial resistance market on the basis of indication, drug class, mechanism of action, pathogen.

  Australia Antimicrobial Resistance Market Report Highlights

Aspects	Details
By Indication	Complicated Urinary Tract Infections (cUTI) Blood stream infections Acute bacterial skin and skin structure infections (ABSSSI) Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP) Community acquired pneumonia (CAP) Others
By Drug Class	Combination therapies Tetracyclines Cephalosporins Glycopeptides and Lipoglycopeptides Oxazolidinones Others
By Mechanism of Action	Protein Synthesis Inhibitors Cell Wall Synthesis Inhibitors Others
By Pathogen	Klebsiella pneumoniae Pseudomonas aeruginosa Staphylococcus aureus Enterococcus Spp Others Escherichia coli

Author Name(s) : Mansi Pardeshi | Roshan Deshmukh

^*Terms and Conditions Apply